• Explore /
  • Poster
  • / Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.

Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.

Abstract Poster

Authors

null

Michael J. Overman

MD Anderson Cancer Center, Houston, TX

Michael J. Overman , Sara Lonardi , Ka Yeung Mark Wong , Heinz-Josef Lenz , Fabio Gelsomino , Massimo Aglietta , Michael Morse , Eric Van Cutsem , Raymond S. McDermott , Andrew G Hill , Michael B. Sawyer , Alain Hendlisz , Bart Neyns , Magali Svrcek , Ajlan Atasoy , Huanyu Zhao , Ming Lei , Scott Kopetz , Thierry Andre

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT02060188

Citation

J Clin Oncol 37, 2019 (suppl 4; abstr 635)

DOI

10.1200/JCO.2019.37.4_suppl.635

Abstract #

635

Poster Bd #

K20

Abstract Disclosures

Similar Posters

First Author: Michael J. Overman

First Author: Heinz-Josef Lenz

First Author: Thierry Andre

First Author: Heinz-Josef Lenz